Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Recent immunotherapy advances in RCC

Prof. David McDermott, MD, of Beth Israel Deaconess Medical Center, Boston, MA, discusses novel treatments in renal cell carcinoma (RCC). At 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. McDermott focusses on PD1 blockade studies such as KEYNOTE-426 (NCT02853331), where pembrolizumab is combined with axitinib, or KEYNOTE-427 (NCT02853344), where pembrolizumab is used as monotherapy in untreated RCC. Prof. McDermott moves on to explain that patients with tumour PDL-1 expression have enhanced response to such treatment.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.